Skip to main content

UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine

October 21, 2019 | Joanne Morrison

Kathleen M. Neuzil, MD, MPH

Dr. Neuzil Has Played an Important Leadership Role in Bridging Science and Policy to Serve the World’s Most Vulnerable Populations

Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization.

Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.

Dr. Neuzil, who is also the Division Head for Geographic Medicine at UMSOM, a member of the UMSOM Executive Committee, and Chair of the Dean’s Culture Transformation Advisory Committee, is one of the world’s most influential research scientists and advocates in vaccine development and policy. She currently serves as the only U.S. member of the World Organization Strategic Advisory Group of Experts on Immunization (SAGE).

“This is an extraordinarily well-deserved recognition for Dr. Neuzil and for her leadership in academic medicine,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. Dr. Neuzil’s pathbreaking vaccine and global health research has been preeminent in shaping and accelerating the most important global vaccine policies, impacting millions of people worldwide every year. She is most deserving of this high honor.”

Throughout her career, Dr. Neuzil has conducted pivotal clinical and epidemiologic research, yielding high profile publications that inform policy decisions and public health actions. At the global non-profit PATH, she was instrumental in the introductions of rotavirus, HPV, and Japanese encephalitis vaccines into low resource countries. At UMSOM’s CVD, she leads a large Gates-funded consortium (TyVAC) to accelerate the introduction of typhoid vaccines into low resource countries and has a robust influenza research program, including a Collaborative Influenza Vaccine Innovation Center (CIVIC) Clinical Core to develop and test more broadly reactive and longer lasting influenza vaccines. Her research capabilities are complemented by 20 years of involvement in domestic and international policy.

“This is truly an honor to be a member of the National Academy of Medicine,” said Dr. Neuzil, who is also dedicated to training and mentoring the next generation of global health and vaccinology researchers.

Over the course of her career she has received numerous awards. Among them, in 2018 she was named in the Daily Record Maryland’s Top 100. In 2016, she received the Vanderbilt University School of Medicine Distinguished Alumna Award, and in 2014 she was named by Vaccine Nation as “One of 50 Most Influential Persons in Vaccines.”

Dr. Neuzil received her BS (Summa cum laude) in Zoology from the University of Maryland, College Park. She received her MD AOA (Alpha Omega Alpha Medical Honor Society) from Johns Hopkins University School of Medicine, and her MPH from Vanderbilt University School of Medicine. Dr. Neuzil completed her residency in Internal Medicine and fellowship in Infectious Diseases at Vanderbilt University School of Medicine.

The University of Maryland School of Medicine now has several current members of the National Academy of Medicine: William T. Carpenter, MD, Professor of Psychiatry and Former Director of the Maryland Psychiatric Research Center; Claire M. Fraser, PhD, The Dean’s Endowed Professor, Professor of Medicine and Director of the Institute for Genome Sciences; Robert C. Gallo, MD, the Homer and Martha Gudelsky Distinguished Professor in Medicine and Co-Founder & Director, Institute of Human Virology; Howard Goldman, MD, Professor of Medicine; Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor, Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founding Director, Center for Vaccine Development & Global Health; E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. PhD, MBA; and Donald E. Wilson, MD, Dean Emeritus, University of Maryland School of Medicine; and now Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health.

About the National Academy of Medicine (NAM)

New NAM members are elected by current members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health. The newly elected members bring NAM’s total membership to 2,178 and the number of international members to 159.

Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the National Academy of Medicine addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors. NAM works alongside the National Academy of Sciences and National Academy of Engineering to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies of Sciences, Engineering, and Medicine also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding. With their election, NAM members make a commitment to volunteer their service in National Academies activities.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

Contact

Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
newsletter@som.umaryland.edu

Joanne Morrison
Director of Marketing and Public Relations
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office: (410) 706-2884
Mobile: (202) 841-3369

Related stories

    Tuesday, May 21, 2024

    University of Maryland School of Medicine Launches Vaccine Development Program to Prevent Sepsis in Newborns

    University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded up to $3.96 million over three years to develop and test a vaccine in an animal model that could eventually be used in pregnant women to prevent sepsis in newborns and infants.


    Wednesday, April 05, 2023

    UM School of Medicine Researchers Chart Path Forward on Developing mRNA Vaccines for Infections Beyond COVID-19

    After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza. Last month, UMSOM faculty in the Center for Vaccine Development and Global Health (CVD) launched a new clinical trial to investigate the use of mRNA technologies to create a vaccine against malaria. CVD Director Kathleen M. Neuzil, MD, MPH, FIDSA also provided commentary in the nation’s leading medical journal on the feasibility of using mRNA to develop a universal influenza vaccine that could eliminate the need for seasonal shots.


    Monday, July 18, 2022

    New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field

    Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.


    Wednesday, January 26, 2022

    Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing

    A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).


    Wednesday, October 30, 2019

    UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of Medicine (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.


    Monday, August 19, 2019

    UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.

    Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).


    Wednesday, July 17, 2019

    Vaccines Tested in UM School of Medicine’s Center for Vaccine Development Protect Children Around the World

    For 30 years, the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) has collaborated with the Pediatric Center of Frederick to test vaccines used in pediatric care.


    Friday, March 08, 2019

    UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia

    Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.


    Wednesday, December 26, 2018

    Multicenter Trial Supports Use of Topical Antibiotic as a Tool to Eliminate Staph Colonization in NICU Babies

    A team of doctors led by Karen L. Kotloff, M.D., University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), has performed a clinical trial involving multiple hospitals that tested the effectiveness of applying a topical antibiotic known as mupirocin for prevention of Staphylococcus aureus (SA) infection in babies in the neonatal intensive care unit (NICU). This study was published in the journal Pediatrics.


    Thursday, December 20, 2018

    Data From Largest Global Diarrheal Disease Study Available to Scientists on Public Sites

    Data collected from the Global Enteric Multicenter Study (GEMS), a multi-site research project studying diarrheal diseases that was designed and coordinated by researchers in the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), are now available to scientists on two online data resources.


    Monday, December 03, 2018

    UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa

    A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.


    Friday, November 02, 2018

    UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel

    Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.


    Sunday, October 28, 2018

    American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research

    Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).


    Thursday, September 28, 2017

    UM SOM Vaccine Expert Warns of Risks of Influenza to Older Populations

    “Protect yourself and others by getting the flu shot” was the message from Kathleen Neuzil, MD, MPH, FIDSA, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM). Dr. Neuzil was among the speakers at a press conference hosted by the National Foundation for Infectious Diseases. U.S. Secretary of Health and Human Services, Thomas E Price, MD, also spoke at the press conference and urged people to get their flu shot. The panel members all received their flu shots following the press conference.


    Friday, August 18, 2017

    Tenth Annual Kids Mini-Med School Celebrates Graduation Day

    In 2008, the University of Maryland School of Medicine expanded its Mini-Med School program to Kids Mini-Med at the Salvation Army’s Franklin Square Boys & Girls Club in West Baltimore. Doctors from the School visited the camp weekly to teach about health and encourage the young campers (ages 5 to 13) to consider careers in science and medicine. The idea took off and over the past decade, our faculty have touched the lives of several hundred campers.


    Tuesday, August 01, 2017

    Preeminent UM SOM Scientist Elected to National Foundation for Infectious Diseases Board

    Kathleen M. Neuzil, MD, MPH, FIDSA, Professor of Medicine and Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), was elected to serve a three-year term to the Board of Directors for the National Foundation for Infectious Diseases (NFID).